Clinical Trials Browser

Phase 2 × Interventional × adavosertib × Clear all

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT02513563 2026-02-19

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Phase 2 Completed

42 enrolled 12 charts

Lung Neoplasms

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03668340 2026-01-12

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Phase 2 Active not recruiting

Uterine Neoplasms

NCT04439227 2025-10-31

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03284385 2025-10-27

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2 Completed

72 enrolled 29 charts

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT03253679 2023-10-17

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Phase 2 Completed

31 enrolled 13 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

95 enrolled 61 charts

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Phase 2 Completed

208 enrolled 27 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT01357161 2023-09-21

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Phase 2 Completed

136 enrolled 15 charts

Ovarian Neoplasms

NCT01164995 2023-09-07

M10MKO

Phase 2 Completed

Carcinoma, Ovarian Epithelial

NCT02576444 2022-12-28

OLAPCO

Phase 2 Terminated

67 enrolled 10 charts

Neoplasms

NCT05212025 2022-06-14

Adavosertib and Gemcitabine in Advanced Pancreatic

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03012477 2021-11-23

CISPLATIN + AZD-1775 In Breast Cancer

Phase 2 Completed

34 enrolled 9 charts

Triple-negative Metastatic Breast Cancer

NCT02593019 2021-03-19

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Phase 2 Completed

Small Cell Lung Carcinoma

NCT02666950 2019-09-06

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Completed

3 enrolled 11 charts

MyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT02688907 2018-09-20

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Phase 2 Terminated

Small Cell Lung Carcinoma

NCT02087241 2017-03-29

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Phase 2 Terminated

22 enrolled 15 charts

Lung Neoplasms